Florence Delie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3658596/publications.pdf Version: 2024-02-01



FLODENCE DELLE

#	Article	IF	CITATIONS
1	Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1-9.	2.0	884
2	A Human Colonic Cell Line Sharing Similarities With Enterocytes as a Model to Examine Oral Absorption: Advantages and Limitations of the Caco-2 Model. Critical Reviews in Therapeutic Drug Carrier Systems, 1997, 14, 66.	1.2	345
3	The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systemsâ~†. Advanced Drug Delivery Reviews, 2007, 59, 1162-1176.	6.6	258
4	Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. International Journal of Pharmaceutics, 2006, 326, 174-181.	2.6	166
5	Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. International Journal of Pharmaceutics, 2004, 286, 131-145.	2.6	142
6	Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. International Journal of Pharmaceutics, 2007, 331, 190-196.	2.6	110
7	Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. European Journal of Pharmaceutical Sciences, 2009, 36, 465-473.	1.9	106
8	Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Journal of Controlled Release, 2010, 144, 324-331.	4.8	93
9	Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. European Journal of Pharmaceutical Sciences, 2009, 38, 230-237.	1.9	69
10	Fluorescent biodegradable PLGA particles with narrow size distributions: Preparation by means of selective centrifugation. International Journal of Pharmaceutics, 2007, 342, 222-230.	2.6	58
11	Characterization of V3 BRU peptide-loaded small PLGA microspheres prepared by a (w1/o)w2 emulsion solvent evaporation method. International Journal of Pharmaceutics, 1994, 111, 137-145.	2.6	56
12	PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment. Pharmaceutics, 2020, 12, 439.	2.0	53
13	In vivo photodynamic activity of photosensitizer-loaded nanoparticles: Formulation properties, administration parameters and biological issues involved in PDT outcome. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 43-53.	2.0	52
14	Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation. International Journal of Pharmaceutics, 2018, 535, 444-451.	2.6	48
15	Imaging the porous structure in the core of degrading PLGA microparticles: The effect of molecular weight. Journal of Controlled Release, 2018, 286, 231-239.	4.8	44
16	GRP78 Protein Expression in Ovarian Cancer Patients and Perspectives for a Drug-Targeting Approach. Journal of Oncology, 2012, 2012, 1-5.	0.6	43
17	Novel self-associative and multiphasic nanostructured soft carriers based on amphiphilic hyaluronic acid derivatives. Carbohydrate Polymers, 2012, 87, 444-451.	5.1	40
18	Study of the influence of several stabilizing agents on the entrapment and in vitro release of pBC 264 from poly(lactide-co-glycolide) microspheres prepared by a W/O/W solvent evaporation method. Pharmaceutical Research, 1996, 13, 1127-1129.	1.7	38

FLORENCE DELIE

#	Article	IF	CITATIONS
19	Interaction of biodegradable nanoparticles with intestinal cells: The effect of surface hydrophilicity. International Journal of Pharmaceutics, 2010, 390, 45-52.	2.6	33
20	Nanoparticle Formulation Improves the Anticonvulsant Effect of Clonazepam on the Pentylenetetrazole-Induced Seizures: Behavior and Electroencephalogram. Journal of Pharmaceutical Sciences, 2014, 103, 2509-2519.	1.6	30
21	Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 207-213.	2.0	29
22	Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia. Journal of Controlled Release, 2016, 232, 93-102.	4.8	29
23	Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 253-261.	2.0	28
24	Atorvastatin-Loaded Hydrogel Affects the Smooth Muscle Cells of Human Veins. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 574-581.	1.3	26
25	Perivascular medical devices and drug delivery systems: Making the right choices. Biomaterials, 2017, 128, 56-68.	5.7	26
26	GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Targeted Oncology, 2013, 8, 225-230.	1.7	23
27	Functionalized PLA polymers to control loading and/or release properties of drug-loaded nanoparticles. International Journal of Pharmaceutics, 2018, 548, 771-777.	2.6	21
28	Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 246-258.	2.0	20
29	Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity. Journal of Drug Targeting, 2009, 17, 599-609.	2.1	19
30	Pharmacological prevention of intimal hyperplasia: A state-of-the-art review. , 2022, 235, 108157.		19
31	Role of PAR-4 in ovarian cancer. Oncotarget, 2015, 6, 22641-22652.	0.8	17
32	Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells. Oncoscience, 2014, 1, 262-271.	0.9	16
33	Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?. Oncotarget, 2017, 8, 107176-107187.	0.8	16
34	In ovo method for evaluating the effect of nutritional therapies on tumor development, growth and vascularization. Clinical Nutrition Experimental, 2015, 2, 9-17.	2.0	14
35	Quenching-induced deactivation of photosensitizer by nanoencapsulation to improve phototherapy of cancer. Journal of Drug Targeting, 2009, 17, 619-626.	2.1	13
36	Polymeric Nanoparticles for Drug Delivery to the Posterior Segment of the Eye. Chimia, 2005, 59, 344-347.	0.3	12

FLORENCE DELIE

#	Article	IF	CITATIONS
37	Evaluating intimal hyperplasia under clinical conditions. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 427-436.	0.5	12
38	Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model. Nanomedicine, 2009, 4, 135-143.	1.7	11
39	Bioguided identification of pentacyclic triterpenoids as anti-inflammatory bioactive constituents of Ocimum gratissimum extract. Journal of Ethnopharmacology, 2021, 268, 113637.	2.0	11
40	Cytotoxicity of a new tirucallane derivative isolated from Stereospermum acuminatissimum K. Schum stem bark. Natural Product Research, 2021, 35, 1-6.	1.0	10
41	Anti-KDEL-coated nanoparticles: A promising tumor targeting approach for ovarian cancer?. Biochimie, 2012, 94, 2391-2397.	1.3	9
42	Design and characterization of a perivascular PLGA coated PET mesh sustaining the release of atorvastatin for the prevention of intimal hyperplasia. International Journal of Pharmaceutics, 2018, 537, 40-47.	2.6	9
43	Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines. AAPS PharmSciTech, 2021, 22, 36.	1.5	6
44	Bioadhesive Hyaluronic Acid/Dopamine Hydrogels for Vascular Applications Prepared by Initiator-Free Crosslinking. International Journal of Molecular Sciences, 2022, 23, 5706.	1.8	6
45	In vitro blood brain barrier models as a screening tool for colloidal drug delivery systems and other nanosystems. International Journal of Biomedical Nanoscience and Nanotechnology, 2010, 1, 133.	0.1	5
46	New high throughput screening method for drug release measurements. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 151-157.	2.0	5
47	Antiproliferative activity of a new xanthone derivative from leaves of <i>Garcinia nobilis</i> Engl Natural Product Research, 2021, 35, 5604-5611.	1.0	4
48	Malignant ascites: a source of therapeutic protein against ovarian cancer?. Oncotarget, 2019, 10, 5894-5905.	0.8	3
49	In Michael Moeller's spirit. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 1	2.0	0
50	Perivascular Administration of Atorvastatin Loaded in Microparticles and Hyaluronic Acid Gel to Prevent Intimal Hyperplasia in Venous Graft. European Journal of Vascular and Endovascular Surgery, 2019, 58, e99-e100.	0.8	0